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Abstract 
Inflammation chronic diseases in gingiva and periodontium tissue cause destruction of alveolar bone. 
Periodontopathy bacteria cause periodontal tissue destruction by host cell activating system, such as prostaglandin. 
PGE2 induce bone resorption and MMP secretion (Academic report, 1999). Prostaglandin E2 (PGE2) is formed as a 
result of the metabolism of arachidonic acid. It participates in inflammatory response. Prostaglandin cause alveolar 
bone destruction by osteoclast activating. Beside it, it enhance calcium metabolism. 
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Inflammation chronic diseases in 
gingiva and periodontium tissue cause 
destruction of gingiva connective tissue, 
periodontal ligament, and alveolar bone. 
Clinically, the inflammation is seen redness, 
swelling, and bleeding on probing. In cellular 
and molecular, inflammation process is 
showed by cellular infiltration and releasing 
some of cytokine. The main provoking factor 
induce gingiva tissue inflammation is biofilm 
bacteria (dental plaque) on teeth surface or 
gingiva interfaces.1  Periodontopathy bacteria 
cause periodontal tissue destruction by host 
cell activating and system to produce and 
release enzyme and the other molecule. 
These can destroy periodontal tissue and this 
activity will be regulated by inflammation 
mediator.2 
The bacteria will invade in 
periodontal tissue and release soluble 
bacterial factor. One of soluble bacterial 
factor is lipopolysacharide (LPS). LPS is play 
role in pathogenesis of alveolar bone 
destruction. LPS is potent material for 
stimulating bone resorption in vitro and in vivo. 
LPS induce production of osteoclast in bone 
marrow culture or injected in femur bone. It is 
showed by number of osteoclast in increasing 
and infiltration on bone surface. LPS also 
induce some locally factor production, such 
as Tumor Necrosis Factor - α (TNF-α), 
interleukin 1 (IL-1), and prostaglandin E2 (PGE2) 
from macrophage, fibroblast, and osteoblast 
cell in inflammation periodontal tissue.3 The 
aim of this study is to know the role 
prostaglandin (PGE2) in alveolar bone 
destruction. 
 
PROSTAGLANDIN E2 (PGE2) 
PGE2 is eicosanoid vasoactive that 
produced by monocyte and fibroblast. 
Eicosanoid signal transduction pathways are 
highly conserved across vertebrate species. 
The prostaglandins, a subset of the eicosanoid 
family of signaling molecules, are involved in a 
number of physiological processes in many 
tissues. Functions of Prostaglandins are a 
variety of physiological effects including: 
1. Activation of the inflammatory response, 
production of pain, and fever. When 
tissues are damaged, white blood cells 
flood to the site to try to minimize tissue 
destruction. Prostaglandins are produced 
as a result. 
2. Blood clots form when a blood vessel is 
damaged. A type of prostaglandin 
called thromboxane stimulates 
constriction and clotting of platelets. 
Conversely, PGI2, is produced to have 
the opposite effect on the walls of blood 
vessels where clots should not be 
forming. 
3. Certain prostaglandins are involved with 
the induction of labor and other 
reproductive processes. PGE2 causes 
uterine contractions and has been used 
to induce labor.  
4. Prostaglandins are involved in several 
other organs such as the gastrointestinal 
tract (inhibit acid synthesis and increase 
secretion of protective mucus), increase 
blood flow in kidneys, and leukotriens 
promote constriction of bronchi 
associated with asthma. 
Prostaglandins are synthesized from 
arachidonic acid (AA) first by cyclooxygenase 
(Cox)1 or 2, which convert AA into PGH2. This 
precursor PG is further processed by isoform 
specific cytosolic or microsomal prostaglandin 
synthases (c/mPGES) to become PGE2 or one 
of several other effector prostaglandins. The 
roles of Cox1 and Cox2 in prostaglandin 
production do not wholly overlap; Cox1 
appears to be responsible for the majority of 
constitutive signaling, while Cox2 acts in an 
inducible fashion. It has been suggested that 
Cox1 and cPGES, and Cox2 and mPGES, 
respectively, work in cooperation. This model 
may oversimplify the role of the two 
prostaglandin syntheses, as increasing 
evidence implies that the requirement of 
each enzyme for PG production is specific to 
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both cell type and function. PGE2 signals in 
either an autocrine or paracrine manner 
through four specific G protein coupled E 
prostanoid (EP) receptors. Positive signal 
transduction receptors include EP1, which 
triggers mobilization of intracellular Ca2+, and 
EP2 and EP4, which both stimulate cyclic AMP 
(cAMP) production. EP3 acts as a negative 
effector to inhibit cAMP. There is evidence to 
indicate that EP2 and EP4 are affected 
differently by PGE2; EP4 quickly becomes 
desensitized to PGE2 and cannot bind its 
metabolites, while EP2 displays no such 
desensitization and is able to bind several 
PGE2 metabolites with varying affinities. This 
would imply that PGE2 signaling is regulated 
distinctly on the levels of Cox, PGES, and EP 
receptors though no conclusive results have 
yet been produced to support this model.4 
PGE2 induce bone resorption and 
MMP secretion.5 Prostaglandin E2 (PGE2) is 
formed as a result of the metabolism of 
arachidonic acid. It participates in 
inflammatory response. Pro inflammatory 
effect of PGE2 are increasing vasodilatation, 
enhancing responsiveness of receptors to 
painful stimuli, releasing of collagenase by 
inflammatory cells and activation of 
osteoclast thereby causing bone resorption.6 
PGE2 is a derivative of arachidonic acid that 
induces periosteal and endocortical bone 
formation, principally by stimulating local 
osteoprogenitor cells on the adjacent 
endocortical surface. The anabolic effect of 
PGE2 demonstrated in long bones may also 
occur in the mandible. Particularly as local 
delivery of prostaglandin E1 (PGE1) has been 
shown to enhance the formation of 
mandibular alveolar bone, reorganization of 
adjacent cells in the periodontal ligament 
and cementum formation. The positive effect 
of PGE2 on bone deposition has been 
reported with doses as low as 1 mg/kg per 
day delivered subcutaneously into different 
animal models over extended periods of 
time.7  
 
ALVEOLAR BONE RESORPTION 
Bone is a dynamic multifunctional 
organ that is comprised of a structural 
framework of calcified matrix containing 
populations of many cell types including 
chondrocytes, osteoblasts, osteocytes, 
osteoclasts, endothelial cells, monocytes, 
macrophages, lymphocytes, and 
hematopoeitic cells. Bone tissue is constantly 
being remodeled throughout life in response 
to hormonal signals, paracrine and autocrine 
factors, and physical stresses.8  
Alveolar bone is remineralized 
connective tissue. It is part of maxillary and 
mandible that support teeth. Alveolar bone is 
consist anorganic matrix (67 %) and organic 
(33 %). Organic matrix is consist 28 % collagen 
and 5 % non collagen.9 Alveolar bone can be 
destruction by overloading of mastication and 
plaque bacteria activity in periodontal 
diseases. Plaque bacteria cause 
differentiation of bone progenitor cell to be 
osteoclast and stimulate gingival cell to 
release inflammation mediators.10 The role of 
osteoclasts in causing bone loss involved pro-
inflammatory cytokines such as IL-1 (interleukin 
-1), IL-6, TNF-β (tumor necrosis factor – β), GM-
CSF, and prostaglandin E2. These cytokines 
and prostaglandins were found to increase 
osteoclast proliferation.  
Bone resorption is complex process 
that related by bone surface loss (lacuna 
howship) and increasing of number of 
multinuclear cell (osteoclast) morphologically. 
Osteoclast is from hemopoetic system, 
monocyte and macrophage. Monocyte and 
macrophage is differenced by cell fusion to 
multinuclear cell. It is stimulated by local and 
systemic factor. When osteclast is active, 
osteoclast produces hydrolytic enzyme. This 
enzyme will digested bone organic materials.3 
Alveolar bone resorption in 
periodontal disease is related by bacteria and 
host interaction. Bacteria plaque products 
induce progenitor bone cells differentiation to 
be osteoclast and induce gingiva cells to 
release inflammatory mediator. Inflammatory 
mediator also influences progenitor bone cells 
differentiation. Plaque product and 
inflammatory mediator can inhibit activity and 
number of osteoblast or progenitor cell 
directly. Host cells also release some factors 
that can induce bone resorption, such as 
prostaglandin and its precursors, IL 1-α, IL 1-β, 
and TNF-α.11  
The remodeling process involves four 
following steps: activation, resorbtion, reversal, 
and formation.8 
1. Activation. The initiation of osteoclastic 
bone resorption depends on the 
interaction between cells of the 
osteoblastic and hematopoietic system. 
Fibroblasts secrete collagenase and 
other matrix-destroying enzymes, leading 
to altered tissue integrity. Fibroblast 
growth factor-23 (FGF23) was first 
discovered as an important factor for 
mineral homeostasis. Osteoblastic cells 
can activate hematopoietic cells to 
differentiate into bone resorbing 
osteoclasts through the production of 
macrophage colony stimulating factor 
(M-CSF) and receptor activator of NFB 
ligand (RANKL). Lining cells of 
osteoblastic origin on the bone surface 
may also play a role by secreting 
proteolytic enzymes that remove a 
protein layer which normally covers the 
mineralized matrix. 
2. Resorption. Osteoclasts bind to the 
mineralized matrix through vitronectin 
receptors and then form their resorbing 
apparatus consisting of a ruffled border. 
Resorbing apparatus will secrete 
hydrogen ions and matrix degrading 
enzymes, particularly Cathepsin K. This 
permits the establishment of a low pH 
and a high concentration of enzymes 
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that can degrade collagen quite 
effectively at that low pH. In addition to 
this cellular compartmentalization there 
may be a compartmentalization of the 
entire bone remodeling unit because the 
lining cells remain intact above the 
osteoclastic resorption and osteoblastic 
formation sites. This might allow for 
growth factors released from osteoclasts 
or matrix during resorption to remain for 
longer and at more effective 
concentrations during the next phase. 
3. Reversal. After osteoclastic resorption is 
complete there is a reversal phase during 
which mononuclear cells, which may be 
either of the mesenchymal or 
hematopoietic lineages, complete the 
removal of matrix and prepare the bone 
for formation by laying down a “cement 
line” of non-collagen proteins. 
4. Formation. In the formation phase 
osteoblasts lay down matrix, which 
becomes gradually mineralized. As each 
layer of osteoblasts forms its assigned 
amount of matrix it either undergoes 
apoptosis, or becomes buried in the 
matrix as an osteocyte. As this process of 
replacing the resorption cavity is 
completed, some of the osteoblasts may 
remain on the surface as lining cells.  
  
THE ROLE OF PROSTAGLANDIN (PGE2) IN 
ALVEOLAR BONE DESTRUCTION 
Oral bacteria in dental plaque 
invade in periodontal tissue. It will release 
soluble bacteria factor, such as 
lipopolysacharide (LPS), and penetrate to 
sulcular epithelium.12 LPS induce inflammation 
in periodontal tissue by activating host 
response (macrophage, fibroblast, and 
osteoblast) to produce pro-inflammatory 
mediator, such as vasoactive amine 
(histamine and serotonin), arachidonic acids 
(prostaglandin and leukotrin), and cytokine 
(tumor necrosis factor and interleukin). 2 
These product recruit neutrophils to 
the area and influence chemotaxis. 
Vasoactive and prostaglandin cause the 
vessels to dilate or increasing of permeability 
of gingiva vessel. It causes passage of virtually 
all of the component of the blood into the 
connective tissue, such as pro-inflammatory 
mediator, complement, plasma protease, 
plasmin and kinin. Pro-inflammatory mediator 
will influence physiology system, especially 
prostaglandin.2,3,13  
Cox 1 is expressed in normal bone, 
while cox 2 expressions are up regulated 
during bone repair and under pathological 
condition such as inflammation and 
neoplasia. Thus, the skeleton is abundantly 
supplied with prostaglandins, especially PGE2.  
Prostaglandin are synthesized and secreted 
by localized host cell response have been 
shown to stimulate osteoclastic bone 
resorption. PGE play a stimulatory or an 
inhibitory role in bone metabolism, depend on 
the physiological or pathological 
circumstances. PGE2 mediated resorption 
contributes significantly to bone loss related 
inflammation diseases and in response to 
prolonged immobilization.14 
Prostaglandin E1, E2 and F2 (PGF2) are 
potent stimulators of bone resorption. Some 
studies show PGE2 will increase alveolar bone 
resorption and the effective dose is 10-8M. If 
the dose is more than 10-8M, alveolar bone 
resorption or decalsification will not 
increase.15,16,17 
The anabolic effect of prostaglandin 
on bone has been demonstrated by systemic 
administration on PGE2, which stimulates bone 
formation and increases bone mass in infant 
and animals. Under specific pathological 
condition, prostaglandin, especially PGE2 can 
stimulate bone resorption by increasing the 
amount and functional activity of osteoclast.14 
The action prostaglandin induces 
alveolar bone resorption by activating 
osteoclast activity to release calcium ion on 
bone surface in both in vivo and in vitro. It has 
been shown that hormones and cytokines 
involved in bone resorption can stimulate cox 
2 and prostaglandin synthesis. Experimental 
animal carrying genes that have been made 
inoperative for cox 2 and PG receptors 
(knockout mice) have impaired 
osteoclastogenesis and decreased bone 
resorption. Elevated secretion of inflammatory 
cytokines and PGE2 is related to the bone loss 
taking place in some inflammatory disease, 
including arthritis and periodontitis.14 
Prostaglandin also causes 
hyperplasia of osteoclast population, 
activation of pre-existing osteoclast and 
increasing of osteoclast size. When PGE2 
administer for the first time, PGE2 will stimulate 
maturation of pre-osteoclast like mononuclear 
cells in the perivascular region on the 
periodontium to stimulate fusion of the 
mononuclear cells. Prostaglandin might 
influence proliferation and differentiation 
osteoclast progenitor cells and osteoclast like 
cells to be osteoclast. All of them make 
production of osteoclast increase. They will 
stimulate activity and increase number of 
osteoclast, so releasing of calcium ion will 
increase. Finally, it causes alveolar bone 
resorption.18  
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